Atea Pharmaceuticals, Inc.
AVIR
$3.93
$0.0952.48%
| Weiss Ratings | AVIR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | AVIR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | AVIR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.67 | |||
| Price History | AVIR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -0.27% | |||
| 30-Day Total Return | -3.90% | |||
| 60-Day Total Return | -11.06% | |||
| 90-Day Total Return | 25.42% | |||
| Year to Date Total Return | 15.26% | |||
| 1-Year Total Return | 11.78% | |||
| 2-Year Total Return | -36.64% | |||
| 3-Year Total Return | -89.85% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -28.90% | |||
| 52-Week Low % Change | 33.45% | |||
| Price | AVIR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $5.19 | |||
| 52-Week Low Price | $2.77 | |||
| 52-Week Low Price (Date) | Nov 22, 2023 | |||
| 52-Week High Price (Date) | May 22, 2023 | |||
| Valuation | AVIR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 313.09M | |||
| Enterprise Value | -262.61M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.63 | |||
| Earnings Per Share Growth | 17.04% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 0.56 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $3.70 | |||
| Enterprise Value/EBITDA (TTM) | 2.05 | |||
| Enterprise Value/EBIT | 2.04 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | AVIR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 83.44M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | AVIR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 857 284 8891 | |||
| Address | 225 Franklin Street Boston, MA 02110 | |||
| Website | ateapharma.com | |||
| Country | United States | |||
| Year Founded | 2012 | |||
| Profitability | AVIR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | AVIR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -12.87% | |||
| Return on Equity | -- | |||
| Income Statement | AVIR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -79.97M | |||
| EBITDA (TTM) | -129.47M | |||
| EBIT (TTM) | -129.89M | |||
| Net Income (TTM) | -135.96M | |||
| Net Income Avl. to Common (TTM) | -135.96M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -13.75% | |||
| EPS Diluted (TTM) | -1.63 | |||
| EPS Diluted Growth (Q YOY) | -13.55% | |||
| Balance Sheet | AVIR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 578.11M | |||
| Cash Per Share (Q) | $6.93 | |||
| Total Current Assets (Q) | 590.46M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 555.19M | |||
| Current Ratio (Q) | 18.237 | |||
| Book Value Per Share (Q) | $6.65 | |||
| Total Assets (Q) | 594.97M | |||
| Total Current Liabilities (Q) | 32.38M | |||
| Total Debt (Q) | 2.40M | |||
| Total Liabilities (Q) | 39.78M | |||
| Total Common Equity (Q) | 555.19M | |||
| Cash Flow | AVIR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 40.30M | |||
| Cash from Financing (TTM) | 257.00K | |||
| Net Change in Cash (TTM) | -44.84M | |||
| Levered Free Cash Flow (TTM) | -15.61M | |||
| Cash from Operations (TTM) | -85.40M | |||
